NCT02632305View on ClinicalTrials.gov

A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 13, 2016

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Unresectable Biliary Tract Cancer
Interventions
DRUG

nab-paclitaxel in combination with gemcitabine + cisplatin

Patients with unresectable BTC will be treated with the triple combination of nab-paclitaxel in combination with gemcitabine + cisplatin

Trial Locations (2)

Unknown

Cross Cancer Institute, Edmonton

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

AHS Cancer Control Alberta

OTHER

NCT02632305 - A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer | Biotech Hunter | Biotech Hunter